Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab

Next Previous
Trial Profile

Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Valaciclovir (Primary)
  • Indications Advanced breast cancer; Male breast cancer; Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms STOMP

Most Recent Events

  • 13 Jan 2025 According to a Candel Therapeutics media release, company looking to report updated overall survival data for CAN-2409 from phase 2a clinical trial in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025.
  • 01 Apr 2024 Results published in the International Journal of Radiation Oncology, Biology, Physics
  • 31 Jan 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top